

DAFTAR PUSTAKA

1. Dipro TJ, Talbert CR, Gary YE, dan Wells BG. Diagnosis dan klasifikasi Tuberculosis. In: Wardhani RA, editor. *Pharmacotherapy A Patofisiologi Approach*. 6 ed. New York: The Macgraw Hill Companies; 2013.
2. Kementrian Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberculosis*. Jakarta: Depertemen Kesehatan RI; 2020.
3. El Bouazzi O, Hammi S, Bourkadi JE, Tebaa A, Tanani DS, Soulaymani-Bencheikh R, et al. First line anti-tuberculosis induced hepatotoxicity: Incidence and risk factors. *Pan Afr Med J*. 2016;25:1–10.
4. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis*. 2016;63(7):e147–95.
5. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis an official ATS/CDC/ERS/IDSA clinical practice guideline. Vol. 200, *American Journal of Respiratory and Critical Care Medicine*. 2019. 93–142 hal.
6. IDAI. *Pedoman Pelayanan Medis: Tuberculosis Jilid I*. In Jakarta: Ikatan Dokter Anak Indonesia; 2010.
7. World Health Organization (WHO). *Global Tuberculosis Report 2021*. In Geneva: World Health Organization; 2021.
8. Brooks GF, Carroll KC, Butel JS, Morse SA MT. Jawetz, Melnick, & Adelberg's *Medical Microbiology*. 26th ed. New York: MC Graw-Hill; 2013.
9. Price SA, Wilson LM. *Patofisiologi Konsep Klinis Proses-proses Penyakit*. 6 ed. Jakarta: EGC; 2012.
10. Broaddus VC, Mason R, Ernst J, Lazarus S, Murray J, Nadel J, et al. *Murray & Nadel's Textbook of Respiratory Medicine*. 6 ed. Murray and Nadel's Textbook of Respiratory Medicine. Canada: Elsevier; 2016.
11. Djojodibroto R. *Respirologi (Respirology Medicine)*. 2 ed. Jakarta: EGC; 2015.
12. Kemenkes RI. *Peraturan Menteri Kesehatan Republik Indonesia Nomor 67 Tahun 2016: Pedoman Penanggulangan Tuberculosis*. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016.
13. Kemenkes RI. *Pedoman Nasional Pengendalian Tuberculosis*. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014.

14. World Health Organization (WHO). Operational handbook on tuberculosis. Module 3: Diagnosis Rapid diagnostics for tuberculosis diagnosis. 2020. 56 hal.
15. Maulidia D. Hubungan Antara Dukungan Keluarga dengan Kepatuhan Minum Obat pada Penderita Tuberkulosis di Wilayah Ciputat Tahun 2014 (Skripsi). Jakarta; 2014.
16. PDS Patologi Klinik. Pedoman Nasional Praktek Klinik Patologi Klinik. In Jakarta: Dokter Spesialis Patologi Klinik dan Kedokteran Laboratorium; 2017.
17. Sloane E. Anatomi dan Fisiologi Untuk Pemula. 1 ed. Jakarta: Penerbit Buku Kedokteran; 2004.
18. Paulsen F, Waschke J. Sobotta Atlas of Human Anatomy. Vol. 2 Internal Organs. Vol.2-Urban & Fischer. Jakarta: EGC; 2011. 104 hal.
19. Preace E. Anatomi Dan Fisiologis Untuk Paramedis. 4 ed. Jakarta: Penerbit PT. Gramedia Pustaka Utama; 2010.
20. Sherwood L. Fisiologi Manusia dari Sel. 6 ed. Jakarta: EGC; 2012.
21. Guyton AC HJ. Buku Ajar Fisiologi Kedokteran (Textbook of Medical Physiology). 11 ed. Irawati dkk, editor. Jakarta: EGC; 2008.
22. Ganong WF. Buku Ajar Fisiologi Kedokteran. 22 ed. Jakarta: EGC; 2008.
23. Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *J Clin Exp Hepatol*. 2013;3(1):37–49.
24. Larson A. Drugs and the liver: Metabolism and mechanisms of injury. 2021;
25. Bjornsson E. Drug-induced Liver Injury in Clinical Practice. *Aliment Pharmacol Ther*. 2010;32:3–13.
26. Yew WW, Chang kwok C, Chan., Dhanise P. crossm. Oxidative Stress First-Line Antituberc Drug-Induced Hepatotoxic. 2018;
27. Russmann S, Kullak-Ublick G., Grattagliano I. Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity. In: *Current Medical Chemistry*. 2009.
28. E Kleinman R, Walker WA. Drug-Induced Hepatotoxicity. In: Kleinman, R.E; Goulet OJ, Mieli-Vergani, G; Sanderson, I.R; Sherman, D.M & Shneider B. (eds), editor. *Walker's Pediatric Gastrointestinal Disease*. 5 ed. Hamilton, Ont. ; Lewiston, NY : BC Decker; 2008.
29. Tostmann A, Boeree MJ, Aarnoutse RE, De Lange WCM, Van Der Ven AJAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. *J Gastroenterol Hepatol*. 2008;23(2):192–202.
30. Sarkar S, Ganguly A. Current Overview of Anti-Tuberculosis Drugs: Metabolism and Toxicities. *Mycobact Dis*. 2016;6(2).

31. Wright GD. Back to the future: A new “old” lead for tuberculosis. *EMBO Mol Med*. 2012;4(10):1029–31.
32. Larson A, Graziani A. Isoniazid hepatotoxicity. 2021;
33. Wang P, Pradhan K, Zhong X bo, Ma X. Isoniazid metabolism and hepatotoxicity. *Acta Pharm Sin B*. 2016;6(5):384–92.
34. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: Then and now. *Br J Clin Pharmacol*. 2016;81(6):1030–6.
35. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. *Am J Respir Crit Care Med*. 2006;174(8):935–52.
36. Kim JH, Nam WS, Kim SJ, Kwon OK, Seung EJ, Jo JJ, et al. Mechanism investigation of rifampicin-induced liver injury using comparative toxicoproteomics in mice. *Int J Mol Sci*. 2017;18(7).
37. Cambau E, Williams DL. Anti-Leprosy Drugs: Modes of Action and Mechanisms of Resistance in *Mycobacterium leprae*. *Int Textb Lepr*. 2019;(7):1–33.
38. Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of Pyrazinamide Action and Resistance. 2014;1952(2):1–12.
39. Shih T, Pai C, Yang P, Chang W, Wang N, Hu Y. A Novel Mechanism Underlies the Hepatotoxicity of Pyrazinamide. 2013;57(4):1685–90.
40. Bjornsson E. Review Article: Drug-induced Liver Injury in Clinical Practice. *Aliment Pharmacol Ther*. 2010;32:3–13.
41. David, S & Hamilton J. Drug-Induced Liver Injury. *US Gastroenterol Hepatol Rev*. 2010;6:73–80.
42. Andrade RJ, Robles M, Fernández-Castañer A, López-Ortega S, López-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: A challenge for gastroenterologists. *World J Gastroenterol*. 2007;13(3):329–40.
43. Departemen Kesehatan. *Biotechnology*. Vol. 46. Jakarta: EGC; 2012. 308–316 hal.
44. Gafar F, Arifin H, Jurnalys YD, Yani FF, Fitria N, Alffenaar JWC, et al. Antituberculosis Drug-induced Liver Injury in Children: Incidence and Risk Factors During the Two-month Intensive Phase of Therapy. *Pediatr Infect Dis J*. 2019;38(1):50–3.
45. Amirudin R. *Buku Ajar Ilmu Penyakit Dalam: Fisiologi dan Biokimia Hati*. 5 ed. Jakarta: Interna Publishing; 2009.
46. Kepala B. Peraturan Badan Pengawas Obat Dan Makanan Nomor 18 Tahun 2021 Tentang Pedoman Uji Farmakodinamik Praktikum Obat Tradisional. *Bpom Ri*. 2021;(1):15–24.

47. Yang X, Schnackenberg LK, Shi Q, Salminen WF. Hepatic toxicity biomarkers. *Biomarkers Toxicol.* 2014;241–59.
48. Rosida A. Pemeriksaan Laboratorium Penyakit Hati. *Berk Kedokt.* 2016;12(1):123.
49. Chan K, Unit P, Hospital H, Kong H. Treatment of tuberculosis in presence of hepatic and renal impairment. 2008;13:100–7.
50. Jong E, Conradie F, Bch MB, Man DHI V, Berhanu R, Man DHI V, et al. Consensus statement : Management of drug-induced liver injury in HIV-positive patients treated for TB. 2013;14(3):113–9.
51. Banjuradja I, Singh G, Division CI, Indonesia U. Mekanisme Hepatotoksisitas dan Tatalaksana Tuberkulosis pada Gangguan Hati. 2020;7(2):55–64.
52. Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. *Clin Infect Dis.* 2010;50(6):833–9.
53. Herrmann K, Pistollato F, Stephens ML. Food for thought ... beyond the 3Rs: Expanding the use of human-relevant replacement methods in biomedical research. *ALTEX.* 2019;36(3):343–52.
54. BPOM RI. Peraturan Badan Pengawas Obat Dan Makanan Tentang Pedoman Uji Toksisitas Praklinik Secara in Vivo. *J Chem Inf Model.* 2020;53(9):21–5.
55. Ridwan E. Etika Pemanfaatan Hewan Percobaan dalam Penelitian Kesehatan Ethical Use of Animals in Medical Research. *J Indon Med Assoc .* 2013;63(3):112–6.
56. Naftali AV, Al Farizi GR, Ovikariani O. Studi Pola Penggunaan Obat Anti Tuberkulosis pada Pasien Tuberkulosis Paru. *J Surya Med.* 2022;8(1):161–7.
57. Chen R, Wang J, Zhang Y, Tang S, Zhan S. Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity. *Arch Toxicol.* 2015;89(6):883–97.
58. Bergmeyer HU, Horder H, Rej R. Approved Recommendation (1985) on IFCC Methods for the Measurement of Catalytic Concentration of Enzymes. IFCC Method for Alanine Aminotransferase. *J Clin Chem Clin Biochem.* 1986;24(7):481–95.
59. Abera W, Cheneke W, Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. *Int J Mycobacteriology.* 2016;5(1):14–20.
60. Chaudhary P. Hepatobiliary tuberculosis. *Ann Gastroenterol.* 2014;27(3):207–11.

61. Juliarta IG, Mulyantari NK, I wayan Putu Sutirta Yasa. Gambaran Hepatotoksisitas (ALT / AST) Penggunaan Obat AntiTuberkulosis Lini Pertama Dalam Pengobatan Pasien Tuberkulosis Paru Rawat Inap Di RSUP Sanglah Denpasar Tahun 2014. *E_Jurnal Med.* 2018;7(10).
62. Munawarah M, Djide MN, Santoso A, Wahyudin E, Sartini S, Djabir YY. Pengaruh penggunaan sediaan fixed dose combination (fdc) dibandingkan dengan tablet lepas obat anti-tuberkulosis terhadap peningkatan nilai sgpt dan sgot pada pasien tuberkulosis di balai besar kesehatan paru masyarakat makassar. *Maj Farm dan Farmakol.* 2019;23(1):32–4.
63. Djauhari T, Subchi N, Program M, Fakultas D, Masyarakat K, Airlangga U, et al. *Jurnal Sainika Medika* Pre Eliminary Study Pengaruh Pemberian First Line Drug Antituberculosis Terhadap Jumlah Hydropic Swelling Pada Sel Hepar Tikus Putih Jantan (*Rattus Novergicus Strain Wistar*) Yang Diinduksi Selama dua Minggu Thontowi Djauhari Nur S. 2019;15(1):60–8.
64. Jeharu SA, Putu IG, Ferry A, Putra S, Widayanti NP. Pengaruh Pemberian Variasi Dosis Rifampisin Terhadap Kadar Gamma Glutamyl Transferase dan Alkaline Phosphatase Pada Tikus Putih Galur Wistar strategi Directly Observed Treatment Tahan Asam Positif). *Data terbaru Case.* 2020;1(1):25–34.
65. Chang TE, Huang YS, Su WJ, Perng CL, Huang YH, Hou MC. The role of regular liver function monitoring in antituberculosis drug-induced liver injury. *J Chinese Med Assoc.* 2019;82(7):535–40.
66. Wu S, Xia Y, Lv X, Zhang Y, Tang S, Yang Z, et al. Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China. *BMC Public Health.* 2012;12(1):1. Tersedia pada: *BMC Public Health*

